News | January 21, 2025
Moderna announces updates on pandemic influenza program
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
The demand in Africa for COVID-19 vaccines has declined
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Subscribe To Our Newsletter & Stay Updated
